Belgium· BE-AMP-SAM527351-00
Crysvita 20 mg
A burosumab product containing burosumab, registered in Belgium by Kyowa Kirin Holdings. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Burosumab is registered in 14 of 19 countries.
Countries holding a registration under ATC M05BX05 (burosumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Burosumab · ATC M05BX05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Burosumab
- Manufacturer
- Kyowa Kirin Holdings
- Country
- Belgium (BE)
- ATC code
- M05BX05
- ATC class
- Burosumab
- Defined daily dose
- 2.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb3923463
- be_apb7729072
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
11 interactions on record for burosumab.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Burosumab · interactions on record
11 records
- 9 severe
- 2 moderate
Most severe, free to view
- DihydrotachysterolA11CC02severe
- CalcitriolA11CC04severe
- CalcifediolA11CC06severe
- ParicalcitolA11CC07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Burosumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainCRYSVITA 20 MG SOLUCION INYECTABLEKyowa Kirin Holdings B.V.
- CzechiaCRYSVITAKyowa Kirin Holdings B.V., Hoofddorp
- SwedenCRYSVITA 20 mg Injektionsvätska, lösningKyowa Kirin Holdings B.V.
- PolandCRYSVITAKyowa Kirin Holdings B.V.
- United KingdomCrysvita 20mg/1ml solution for injection vialsKyowa Kirin Ltd
- NorwayCrysvitaKyowa Kirin Holdings B.V.
- United StatesCRYSVITAKyowa Kirin, Inc.
- FinlandCrysvitaKyowa Kirin Holdings B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Crysvita
- Liechtenstein · Crysvita
- Norway · Crysvita
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9ae4edc3-13e7-46c1-9910-e58fade47857 GET /v1/drugs/9ae4edc3-13e7-46c1-9910-e58fade47857?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Crysvita 20 mg",
"name_fr": "Crysvita 20 mg",
"name_nl": "Crysvita 20 mg",
"amp_code": "SAM527351-00",
"strengths": [
"20.0000",
"20.0000",
"45.9100"
],
"pack_count": 2,
"substances": [
"Burosumab",
"Sorbitol",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Burosumab",
"authorisation_numbers": [
"EU/1/17/1262/002"
]
}See everything about burosumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.